We are live on !
Find out more
Rice Hall James & Associates Portfolio holdings
AUM
$2.05B
Turnover
10.59%
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter Est. Return
+19.36%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$2.05B
AUM Growth
+$259M
(+14%)
Cap. Flow
+$4.36M
Cap. Flow % of AUM
Cap. Flow %
0.21%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
255
New
12
Increased
112
Reduced
101
Closed
15
Avg Time Held
5.3
years
Top 10 Avg Time Held
1
year
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oshkosh
OSK
|
+$14.9M |
| 2 |
Upwork
UPWK
|
+$13.9M |
| 3 |
TETRA Technologies
TTI
|
+$10.1M |
| 4 |
Prestige Consumer Healthcare
PBH
|
+$8.64M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$7.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aehr Test Systems
AEHR
|
+$16.9M |
| 2 |
Fabrinet
FN
|
+$11.8M |
| 3 |
CEVA Inc
CEVA
|
+$11.4M |
| 4 |
Amicus Therapeutics
FOLD
|
+$11.1M |
| 5 |
Chart Industries
GTLS
|
+$7.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.48% |
| 2 | Technology | 28.09% |
| 3 | Industrials | 14.98% |
| 4 | Consumer Discretionary | 7.96% |
| 5 | Communication Services | 5.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Ligand Pharmaceuticals
LGND
$6.15B
| $85.4M | 4.15% |
270,052
-13,515
| -5% | -$3.18M |
2015 Q1
45 quarters
|
|
2
ACI Worldwide
ACIW
$5.62B
| $50.6M | 2.46% |
1,006,595
+3,239
| +0.3% | +$141K |
2013 Q2
52 quarters
|
|
3
Arlo Technologies
ARLO
$1.33B
| $50.3M | 2.45% |
3,732,962
+73,074
| +2% | +$990K |
2021 Q4
18 quarters
|
|
|
4
Fabrinet
FN
$11.7B
| $49.2M | 2.4% |
87,577
-18,238
| -17% | -$11.8M |
2020 Q2
24 quarters
|
|
5
Establishment Labs
ESTA
$1.96B
| $48.1M | 2.34% |
560,935
+12,261
| +2% | +$881K |
2020 Q2
24 quarters
|
|
6
XPO
XPO
$21.3B
| $46.2M | 2.25% |
224,878
+579
| +0.3% | +$123K |
2017 Q1
37 quarters
|
|
7
Ziff Davis
ZD
$1.98B
| $43M | 2.09% |
821,496
+21,678
| +3% | +$981K |
2013 Q2
52 quarters
|
|
8
Shift4
FOUR
$2.92B
| $42.5M | 2.07% |
874,492
+26,766
| +3% | +$1.16M |
2023 Q4
10 quarters
|
|
9
Kiniksa Pharmaceuticals
KNSA
$5.69B
| $40M | 1.95% |
624,928
+16,512
| +3% | +$857K |
2020 Q4
22 quarters
|
|
10
Ascendis Pharma A/S
ASND
$16.1B
| $39.6M | 1.93% |
148,644
+258
| +0.2% | +$60.3K |
2020 Q3
23 quarters
|
|
11
Stride
LRN
$3.26B
| $37.9M | 1.84% |
438,981
+541
| +0.1% | +$49.7K |
2020 Q1
25 quarters
|
|
|
12
Prestige Consumer Healthcare
PBH
$2.28B
| $32.6M | 1.59% |
689,692
+168,070
| +32% | +$8.64M |
2018 Q3
31 quarters
|
|
13
Donnelley Financial Solutions
DFIN
$1.33B
| $32.5M | 1.58% |
775,119
-4,918
| -0.6% | -$214K |
2021 Q1
21 quarters
|
|
14
Ituran Location and Control
ITRN
$1.02B
| $29M | 1.41% |
475,496
-56,358
| -11% | -$3.35M |
2013 Q4
50 quarters
|
|
15
Medpace
MEDP
$18.9B
| $28.7M | 1.39% |
54,116
+133
| +0.2% | +$61.4K |
2020 Q4
22 quarters
|
|
16
Armstrong World Industries
AWI
$6.97B
| $28.4M | 1.38% |
177,147
+290
| +0.2% | +$47.4K |
2019 Q2
28 quarters
|
|
17
GoDaddy
GDDY
$13.9B
| $28.1M | 1.37% |
330,474
+11,021
| +3% | +$930K |
2021 Q4
18 quarters
|
|
18
Birkenstock
BIRK
$5.38B
| $27.1M | 1.32% |
629,868
+39,500
| +7% | +$1.6M |
2025 Q4
2 quarters
|
|
19
Clear Secure
YOU
$4.74B
| $27M | 1.32% |
485,011
-92,070
| -16% | -$5.03M |
2024 Q1
9 quarters
|
|
20
Ingevity
NGVT
$2.44B
| $26.2M | 1.28% |
351,203
+6,065
| +2% | +$437K |
2017 Q3
35 quarters
|
|
21
WEX
WEX
$6.55B
| $25.2M | 1.23% |
178,606
-1,708
| -0.9% | -$253K |
2024 Q2
8 quarters
|
|
22
Sportradar
SRAD
$3.73B
| $23.9M | 1.16% |
1,597,682
+15,500
| +1% | +$225K |
2025 Q3
3 quarters
|
|
23
Liquidity Services
LQDT
$1.42B
| $23.8M | 1.16% |
608,476
+11,233
| +2% | +$398K |
2022 Q3
15 quarters
|
|
24
Federal Agricultural Mortgage
AGM
$2.18B
| $23.5M | 1.15% |
118,094
+3,389
| +3% | +$594K |
2018 Q1
33 quarters
|
|
25
BioCryst Pharmaceuticals
BCRX
$2.01B
| $23.3M | 1.14% |
2,332,043
+101,938
| +5% | +$922K |
2023 Q2
12 quarters
|
|
Similar funds
Rice Hall James & Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Rice Hall James & Associates held 255 positions worth $2.05B, up 14% from $1.8B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rice Hall James & Associates's Q2 2026 filing shows 12 new, 112 increased, 101 reduced and 15 closed positions. Its largest new stake was Oshkosh: 106,011 shares worth $16.3M. The largest sale was Aehr Test Systems, an estimated $16.9M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Industrials.
- Rice Hall James & Associates's largest Q2 2026 buy was Oshkosh: 106,011 shares worth $16.3M.
- Rice Hall James & Associates added most to Upwork in Q2 2026, an estimated $13.9M increase.
- Rice Hall James & Associates's biggest Q2 2026 reduction was Aehr Test Systems, cutting an estimated $16.9M.
- Rice Hall James & Associates fully exited Amicus Therapeutics in Q2 2026, selling an estimated $11.1M.
- Rice Hall James & Associates's ten largest holdings make up 24% of its $2.05B portfolio in Q2 2026.
- Rice Hall James & Associates opened 12 new positions and closed 15 in Q2 2026.
- Rice Hall James & Associates's portfolio value rose 14% quarter-over-quarter to $2.05B.
Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.